The conversation discusses hair regrowth progress after 2.5 months using pyrilutamide and minoxidil. Participants note visible improvement in a short time.
User experiencing hair loss on dutasteride; others suggest shedding is normal and to track progress with pictures. Some mention using RU58841 for improvement.
Someone's brother tried Platelet-rich plasma (PRP) for hair loss; it had minimal effect on hair but improved skin appearance. Microneedling at home was suggested as a more sustainable alternative.
PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.
User made progress with topical Finasteride/Minoxidil and topical Dutasteride for hair loss. Microneedling at 1.5mm daily was also mentioned as part of the treatment.
Ultrasound imaging can predict hair shedding and assess hair growth stages by analyzing hair follicle characteristics. The conversation also discusses using ultrasound for personal hair analysis and mentions the potential use of infrared emission for hair treatment.
The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.
Topical spironolactone is considered safe for males but is not very effective for hair loss. Some users suggest trying it since it's already purchased, while others recommend alternatives like clascoterone.
The user experienced initial hair density improvement with finasteride, but later felt scalp pain and a plateau in results. They added alfatradiol for scalp inflammation and divi scalp serum to their routine, and are curious if others have similar experiences.
The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
The user has tried various treatments like Dutasteride, RU58841, Minoxidil, Finasteride, Spironolactone, Pyrilutamide, and Ketoconazole for hair loss without success and is considering a scalp biopsy to diagnose another condition. Others suggest consulting a dermatologist and possibly getting a biopsy, as the issue might not be typical male pattern baldness.
The user experienced eyebrow hair loss after COVID-19 and has not seen regrowth despite using Latisse. They are seeking new treatment options but are cautious about spending money on ineffective solutions.
The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
Hair loss was triggered by a testosterone and Masteron cycle, causing scalp tension and shedding. Topical finasteride, RU58841, and oral minoxidil were used to stop shedding and improve scalp condition.
The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.
The user experiences histamine intolerance with alcohol-based hair loss treatments like Rogaine foam and seeks alternatives. Suggestions include alcohol-free and PPG-free topical minoxidil or finasteride, and trying Spectral products with different solvents.
The conversation is about choosing effective hair loss treatments, specifically discussing RU58841, 5% minoxidil, copper peptides, microneedling, finasteride, dutasteride, and Tretinoin. The user seeks advice on the best topical treatments and prefers to use only 1-2 products.
The user is considering switching from oral to topical minoxidil due to lack of improvement and side effects, while continuing with dutasteride or finasteride. They seek advice from others with diffuse thinning.
An 18-year-old male is experiencing significant hair shedding, particularly from the back of his head, despite normal blood test results except for slightly low vitamin D. A dermatologist prescribed minoxidil for receding temples, but the cause of the shedding remains unclear.
A 25-year-old experiencing hair thinning all over the body and head, despite using minoxidil and having low vitamin D levels, is advised to seek a second opinion from a dermatologist specializing in hair loss. The likely diagnosis is diffuse alopecia areata, which may require treatment with a JAK inhibitor.
Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.
The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.
The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.
Ordering Pyrilutamide from Minoxidilmax to use as an experimental topical treatment for hair loss, with discussion of the carrier used in trials and encouragement from other users.
The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.